葛兰素史克公司正为其实验性抗人H5N1型禽流感疫苗开发一种新的增效剂,以便在禽流感大流行时提高疫苗产量,并希望能在今年年底生产这种新疫苗。公司总裁David Stout说,公司不仅仅试验一种常规疫苗增效剂,同时还在试验第2种改进的疫苗。在世界经济论坛期间,他还告诉记者,“我们认为第2种疫苗效果会更好,2种疫苗都将在4月份进入临床。” GlaxoSmithKline is developing a new synergist for its experimental anti-human H5N1 bird flu vaccine to boost vaccine production during the bird flu pandemic and hopes to produce the new vaccine by the end of this year. David Stout, president of the company, said the company is not just testing a conventional vaccine booster but is also testing a second improved vaccine. During the World Economic Forum, he also told reporters: “We think the second vaccine will work better and both vaccines will enter the clinic in April.”